Regeneron Pharmaceuticals（NASDAQ：REGN）和开发合作伙伴Sanofi（NYSE：SNY）宣布了一项3期临床试验的详细结果，该试验评估了Dupixent（dupilumab）在中度至重度特应性皮炎（AD）的青少年（12至17岁）中的应用。数据在巴黎EADV大会上发表。是达到EASI-75的患者比例（症状改善75％），而美国的主要终点指标是达到IGA 0（透明皮肤）或1（几乎透明）的患者的比例。41.5％接受Dupixent的患者每两个周，并且每四周接受一次药物的患者中有38％达到了EASI-75，而安慰剂则为8％（p<0.001).24% of patients receiving weight-based dosing of Dupixent every two weeks and 18% of those receiving a fixed-dose regimen every four weeks achieved IGA 0 or 1 compared to 2% for placebo (p<0.001).Key secondary endpoints were also met.On the safety front, adverse events (AEs) were observed in 72% of patients in two-week group, 64% in the four-week group and 69% for control. The most frequent AEs were injection site reactions (8.5%, 6% and 3.5%, respectively).The results will support global marketing applications.Dupixent was approved in the U.S. in March 2017 and in Europe six months later for adults with moderate-to-severe AD. It is also approved in Japan and Canada.Previously: Regeneron & Sanofi"s Dupixent successful in late-stage dermatitis study in adolescents (May 16)Now read: Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy"s Entry, Bristol-Myers SucceedsOriginal articleiv>